505 related articles for article (PubMed ID: 16499921)
1. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
2. Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.
Albrecht H; Burke PA; Natarajan A; Xiong CY; Kalicinsky M; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2004; 15(1):16-26. PubMed ID: 14733579
[TBL] [Abstract][Full Text] [Related]
3. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
Albrecht H; Denardo GL; Denardo SJ
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275
[TBL] [Abstract][Full Text] [Related]
4. Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris.
Marty C; Scheidegger P; Ballmer-Hofer K; Klemenz R; Schwendener RA
Protein Expr Purif; 2001 Feb; 21(1):156-64. PubMed ID: 11162401
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
6. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ
Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582
[TBL] [Abstract][Full Text] [Related]
7. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
8. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
9. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains.
Kim YJ; Neelamegam R; Heo MA; Edwardraja S; Paik HJ; Lee SG
J Microbiol Biotechnol; 2008 Jun; 18(6):1186-90. PubMed ID: 18600066
[TBL] [Abstract][Full Text] [Related]
10. A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold.
Desiderio A; Franconi R; Lopez M; Villani ME; Viti F; Chiaraluce R; Consalvi V; Neri D; Benvenuto E
J Mol Biol; 2001 Jul; 310(3):603-15. PubMed ID: 11439027
[TBL] [Abstract][Full Text] [Related]
11. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
12. Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling.
Messerschmidt SK; Kolbe A; Müller D; Knoll M; Pleiss J; Kontermann RE
Bioconjug Chem; 2008 Jan; 19(1):362-9. PubMed ID: 17988079
[TBL] [Abstract][Full Text] [Related]
13. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.
Shan D; Press OW; Tsu TT; Hayden MS; Ledbetter JA
J Immunol; 1999 Jun; 162(11):6589-95. PubMed ID: 10352275
[TBL] [Abstract][Full Text] [Related]
14. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics.
DeNardo SJ; DeNardo GL; DeNardo DG; Xiong CY; Shi XB; Winthrop MD; Kroger LA; Carter P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3213s-3218s. PubMed ID: 10541366
[TBL] [Abstract][Full Text] [Related]
15. Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: effects on tissue retention in vivo.
Huang BC; Davern S; Kennel SJ
J Immunol Methods; 2006 Jun; 313(1-2):149-60. PubMed ID: 16750217
[TBL] [Abstract][Full Text] [Related]
16. Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding.
Xiong CY; Natarajan A; Shi XB; Denardo GL; Denardo SJ
Protein Eng Des Sel; 2006 Aug; 19(8):359-67. PubMed ID: 16760193
[TBL] [Abstract][Full Text] [Related]
17. Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis.
Donà MG; Giorgi C; Accardi L
BMC Cancer; 2007 Jan; 7():25. PubMed ID: 17266749
[TBL] [Abstract][Full Text] [Related]
18. [New type recombinant antibody fragment scFv multimer and cancer targeting].
Guo J; Cai M
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Jun; 20(2):361-5. PubMed ID: 12856620
[TBL] [Abstract][Full Text] [Related]
19. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.
Olafsen T; Tan GJ; Cheung CW; Yazaki PJ; Park JM; Shively JE; Williams LE; Raubitschek AA; Press MF; Wu AM
Protein Eng Des Sel; 2004 Apr; 17(4):315-23. PubMed ID: 15187222
[TBL] [Abstract][Full Text] [Related]
20. Cloning, expression and characterisation of a single-chain Fv antibody fragment against domoic acid in Escherichia coli.
Hu X; O'Dwyer R; Wall JG
J Biotechnol; 2005 Oct; 120(1):38-45. PubMed ID: 16019098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
